Cytotoxicity effects and biochemical investigation of novel tetrakis-phthalocyanines bearing 2-thiocytosine moieties with molecular docking studies

dc.contributor.authorGunsel, Armagan
dc.contributor.authorYildirim, Asli
dc.contributor.authorTaslimi, Parham
dc.contributor.authorErden, Yavuz
dc.contributor.authorTaskin-Tok, Tugba
dc.contributor.authorPiskin, Hasan
dc.contributor.authorBilgicli, Ahmet T.
dc.contributor.authorErden, Yavuz
dc.contributor.authorTaslimi, Parham
dc.date.accessioned2025-10-18T10:05:01Z
dc.date.created2022
dc.date.issued2022
dc.departmentFakülteler, Fen Fakültesi, Biyoteknoloji Bölümü
dc.departmentFakülteler, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümü
dc.description.abstractIn this study, the novel 3-(4-aminopyrimidin-2-ylthio) phthalonitrile (1) as starting material was synthesized and its molecular structure was verified by the experiment of single crystal X-ray diffraction, and it was first brought to the literature. Then, its non-peripherally tetra-substituted phthalocyanines (2,3) and the methylated derivatives (2a,3a) containing cytosine derivative were synthesized herein for the first time. All the compounds used were characterized with various spectroscopic methods such as UV-Vis, FT-IR, H-1 NMR, C-13 NMR and MALDI-TOF MS by obtaining highly satisfactory results. The acetylcholinesterase inhibitor compounds recorded as important therapeutic drugs for the therapy of Alzheimer's disease. So, these novel phthalocyanines effectively inhibited acetylcholinesterase enzyme, with Ki values in the range of 31.75 +/- 5.72 to 107.15 +/- 12.67 mu M. For this enzyme, IC50 values were obtained in the range of 3.41 +/- 0.78 to 10.08 +/- 2.65 mu M. For alpha-glycosidase enzyme, the most effective Ki values of (3) and (3a) were found as 3.41 +/- 0.78 and 5.32 +/- 1.34 mu M, respectively. We used 50 mu L substrates for the acetylcholine esterase and alpha-glycosidase enzymes and 20 mu L enzymes. For AChE, we used distilled water and buffer 800 mu L and 100 mu L, respectively. Also, we pipetted 500 mu L and 300 mu L for alpha-glycosidase and examined the activities. Indeed, the most potent phthalocyanines against both enzymes were recorded for the purpose to investigate interaction modes of these compounds in the active site of the target enzyme. After treatment of compounds, viability was reduced by approximately 25% in cancer cell lines. The cytotoxicity potential of these phthalocyanines against human breast, colon, and prostate cancers demonstrated that these compounds had normal cytotoxic effects.
dc.identifier.doi10.1016/j.inoche.2022.109263
dc.identifier.issn1387-7003
dc.identifier.issn1879-0259
dc.identifier.orcidGunsel, Armagan/0000-0003-1965-1017
dc.identifier.orcidPiskin, Hasan/0000-0001-9927-4930
dc.identifier.orcidTASKIN-TOK, Tugba/0000-0002-0064-8400
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidYarasir, Meryem Nilufer/0000-0002-7327-7137
dc.identifier.orcidGulcin, ilhami/0000-0001-5993-1668
dc.identifier.orcidBILGICLI, Ahmet Turgut/0000-0002-4144-7357
dc.identifier.scopus2-s2.0-85123778112
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.inoche.2022.109263
dc.identifier.urihttps://hdl.handle.net/11772/21012
dc.identifier.volume138
dc.identifier.wosWOS:000788153500004
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofInorganic Chemistry Communications
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subjectPhthalocyanine
dc.subjectSynthesis
dc.subjectCrystal Structure
dc.subjectCytotoxicity
dc.subjectEnzyme Inhibition
dc.subjectMolecular Docking
dc.titleCytotoxicity effects and biochemical investigation of novel tetrakis-phthalocyanines bearing 2-thiocytosine moieties with molecular docking studies
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication03e83980-c1b3-4acd-94a9-b6bc0b0a5695
relation.isAuthorOfPublicationdadfa319-65b8-4543-92b4-bea49e0139e9
relation.isAuthorOfPublication.latestForDiscovery03e83980-c1b3-4acd-94a9-b6bc0b0a5695

Dosyalar